Trial Profile

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 30 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cediranib (Primary) ; Olaparib (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine; Paclitaxel
Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Registrational; Therapeutic Use

24 Sep 2024 Planned End Date changed from 9 Aug 2024 to 23 Aug 2025.
24 Oct 2023 Results assessing pre-specified overall survival analysis, presented at the 48th European Society for Medical Oncology Congress.
12 Sep 2023 Planned End Date changed from 30 Dec 2023 to 9 Aug 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com